Aloiau Athenea N, Bobek Briana M, Pearson Kelly E, Cherry Kendall E, Smith Christopher R, Ketcham John M, Marx Matthew A, Harwood Stephen J
Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.
J Org Chem. 2024 Aug 16;89(16):11525-11536. doi: 10.1021/acs.joc.4c01227. Epub 2024 Jul 29.
In our drug discovery campaigns to target the oncogenic drivers of cancers, the demand for a chemoselective, stereoselective and economical synthesis of chiral benzylamines drove the development of a catalytic zirconium hydride reduction. This methodology uses the inexpensive, bench stable zirconocene dichloride, and a novel tetrabutylammonium fluoride activation tactic to catalytically generate a metal hydride under ambient conditions. The diastereo- and chemoselectivity of this reaction was tested with the preparation of key intermediates from our discovery programs and in the scope of sulfinyl ketimines and carbonyls relevant to medicinal chemistry and natural product synthesis. A preliminary mechanistic investigation conducted into the role of tetrabutylammonium fluoride indicates that formation of a zirconocene fluoride occurs to initiate catalysis. The implications of this convenient activation approach may provide expanded roles for zirconium hydrides in catalytic transformations.
在我们针对癌症致癌驱动因素的药物发现活动中,对手性苄胺进行化学选择性、立体选择性且经济的合成的需求推动了氢化锆催化还原反应的发展。该方法使用价格低廉、在实验室条件下稳定的二氯二茂锆,以及一种新型的四丁基氟化铵活化策略,在环境条件下催化生成金属氢化物。我们用发现计划中的关键中间体的制备,以及与药物化学和天然产物合成相关的亚磺酰基酮亚胺和羰基的范围,测试了该反应的非对映选择性和化学选择性。对四丁基氟化铵作用进行的初步机理研究表明,会形成二茂锆氟化物以引发催化反应。这种便捷的活化方法的意义可能为氢化锆在催化转化中的应用提供更广泛的作用。